Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

GSK Shuts U.S. Plant Due to Bacteria

Karen Brooks & Ben Hirschler  |  August 13, 2015

(Reuters)—Drugmaker GlaxoSmithKline temporarily closed a North Carolina factory on Tuesday after testing at a cooling tower found bacteria that causes deadly Legionnaire’s disease.

The Legionella bacteria were discovered during routine inspections at the site in Zebulon, N.C., the company said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The shutdown is not expected to disrupt supplies of medicines made at the factory, which include GSK’s $7 billion-a-year inhaled respiratory drug Advair (fluticasone propionate). Advair is also made at two other sites in Ware, England, and Evreux, France.

GSK said the shutdown was a precautionary measure and the Zebulon site would reopen when the situation was remedied. The tower is a stand-alone structure that does not come in contact with any products.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The cooling towers will be cleaned and retested before the site goes back into operation. GSK is taking these precautions to ensure the health and safety of our employees, as well as the safety and integrity of our products,” the group said in a statement.

Spokeswoman Jenni Brewer Ligday said 600 workers were sent home or told not to come in while the towers were being cleaned.

City and state officials said the discovery did not warrant a public health alert and that no threat was posed to city drinking water, according to a report in the Charlotte News and Observer newspaper.

The Zebulon plant manufactures around 30 different GSK drugs in all, including malaria drug Malarone (atovaquone and proguanil), HIV treatment Combivir (lamivudine and zidovudine) and Requip (ropinorole hydrochloride) for Parkinson’s disease, but its biggest product line is Advair, for asthma and chronic lung disease.

GSK is also planning to produce its next-generation dry powder inhaled respiratory drugs, such as Breo and Anoro, at Zebulon, although for the moment these are only being made in Ware.

Legionella bacteria are found naturally in warm water and thrive in environments such as hot tubs, cooling towers, water tanks, large plumbing systems and fountains, according to the U.S. Centers for Disease Control and Prevention.

Legionnaire’s disease, a severe kind of pneumonia, is contracted by breathing in mist containing the bacteria. It is not contagious, according to the CDC.

Last week, New York City’s Department of Health ordered the inspection and cleaning of all cooling towers in the city in response to an outbreak of Legionnaire’s’ disease that has claimed 12 lives.

Share: 

Filed under:Drug Updates Tagged with:GlaxoSmithKlineLegionnaire's diseasepublic health

Related Articles

    His and Hers Knees

    September 1, 2008

    Do gender-specific knee implants offer clinical benefits for women?

    GSK Wins U.S. Shingles Vaccine Approval, U.K. Nod for Gene Therapy

    October 23, 2017

    LONDON (Reuters)—GlaxoSmithKline has won U.S. approval for a new and improved shingles vaccine, the second of three key products for which the British drugmaker expects approval this year. It also secured a recommendation from U.K. cost authorities for a $700,000 gene therapy for so-called “bubble boy” disease—a step forward for the field of fixing faulty…

    Glucocorticoids May Decrease White Matter Integrity & Change Gray Matter Volume

    February 27, 2023

    Van der Meulen et al. found the use of both systemic and inhaled glucocorticoids is associated with changes in several brain imaging parameters, including decreased white matter integrity and gray matter volume. Study patients also reported more depressive symptoms and tiredness than controls.

    The Microbiome

    November 1, 2011

    A voyage to (our inner) Lilliput

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences